The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes

Diabetologia

Volumn 49, Issue 2, 2006, Pages 369-374

  Zander, M ^a,b   Madsbad, S ^a   Deacon, C F ^b   Holst, J J ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dipeptidyl peptidase 4; Glucagon; Glucagon like peptide 1; Glycaemic control; Insulin; Metabolism; Metabolite; Treatment; Type 2 diabetes

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INFUSION; DRUG METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIGENS, CD26; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MIDDLE AGED; NITRILES; PEPTIDES; PYRROLIDINES;

EID: 31844433106     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0098-y     Document Type: Article

References (30)

1. Nauck MA, Meier JJ, Creutzfeldt W (2003) Incretins and their analogues as new antidiabetic drugs. Drug News Perspect 16:413-422
2. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
3. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC (1996) Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530
4. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
5. Ritzel R, Orskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38:720-725
6. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
7. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
8. Knudsen LB, Pridal L (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435
9. Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19:877-882
10. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332
11. Deacon CF, Plamboeck A, Moller S, Holst JJ (2002) GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 282:E873-E879
12. Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
13. Ahren B, Holst JJ, Martensson H, Balkan B (2000) Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245
14. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
15. Deacon CF, Hughes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47:764-769
16. Pospisilik JA, Martin J, Doty T et al (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741-750
17. Ahren B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
18. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
19. Ahren B, Gomis R, Standl E, Mills D, Schweizer A (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880
20. Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423
21. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539
22. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B (1996) Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19:843-848
23. 2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-1779
24. Rolin B, Deacon CF, Carr RD, Ahren B (2004) The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 494:283-288
25. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
26. Vilsboll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119
27. Hansotia T, Baggio LL, Delmeire D et al (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335
28. Fehmann HC, Jiang J, Pitt D, Schweinfurth J, Goke B (1996) Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells. Pancreas 13:273-282
29. Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276
30. Hui H, Nourparvar A, Zhao X, Perfetti R(2003) Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144:1444-1455